CD276 and neoplasm: Anti-B7-H3 agents, including MAbs, bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T cells, and radioimmunotherapy agents, have exhibited encouraging anti-tumor activity in preclinical models and have recently entered clinical trials for multiple cancer types [11].